{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:59:14Z","timestamp":1792079954733,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41375-024-02174-1","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T06:02:11Z","timestamp":1708581731000},"page":"803-809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis"],"prefix":"10.1038","volume":"38","author":[{"given":"Long","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-9470","authenticated-orcid":false,"given":"Hao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-3073","authenticated-orcid":false,"given":"Xin-Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"2174_CR1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672\u201381.","journal-title":"Blood"},{"key":"2174_CR2","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.2021014343","volume":"139","author":"G Goyal","year":"2022","unstructured":"Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022;139:2601\u201321.","journal-title":"Blood"},{"key":"2174_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919\u201323.","journal-title":"Blood"},{"key":"2174_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-021-01439-3","volume":"36","author":"J Chen","year":"2022","unstructured":"Chen J, Zhao AL, Duan MH, Cai H, Gao XM, Liu T, et al. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. Leukemia. 2022;36:573\u20136.","journal-title":"Leukemia"},{"key":"2174_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/gcc.22247","volume":"54","author":"DS Nelson","year":"2015","unstructured":"Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B, et al. Map2k1 and map3k1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54:361\u20138.","journal-title":"Genes Chromosomes Cancer"},{"key":"2174_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0651-z","volume":"12","author":"A Tazi","year":"2017","unstructured":"Tazi A, Lorillon G, Haroche J, Neel A, Dominique S, Aouba A, et al. Vinblastine chemotherapy in adult patients with Langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis. 2017;12:95.","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR7","doi-asserted-by":"publisher","first-page":"e43257","DOI":"10.1371\/journal.pone.0043257","volume":"7","author":"MA Cantu","year":"2012","unstructured":"Cantu MA, Lupo PJ, Bilgi M, Hicks MJ, Allen CE, McClain KL. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. Plos One. 2012;7:e43257.","journal-title":"Plos One"},{"key":"2174_CR8","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.1002\/ajh.26119","volume":"96","author":"G Goyal","year":"2021","unstructured":"Goyal G, Abeykoon JP, Hu M, Young JR, Shah MV, Bennani NN, et al. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am J Hematol. 2021;96:E146\u201350.","journal-title":"Am J Hematol"},{"key":"2174_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.16449","volume":"189","author":"A Neel","year":"2020","unstructured":"Neel A, Artifoni M, Fontenoy AM, Tessoulin B, Lorillon G, Cohen-Aubart F, et al. Long-term efficacy and safety of 2Cda (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. Br J Haematol. 2020;189:869\u201378.","journal-title":"Br J Haematol"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1182\/blood.V93.12.4125","volume":"93","author":"A Saven","year":"1999","unstructured":"Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood. 1999;93:4125\u201330.","journal-title":"Blood"},{"key":"2174_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.leukres.2016.01.012","volume":"42","author":"MH Duan","year":"2016","unstructured":"Duan MH, Han X, Li J, Zhang W, Zhu TN, Han B, et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: a single-center retrospective study. Leuk Res. 2016;42:43\u201346.","journal-title":"Leuk Res"},{"key":"2174_CR12","doi-asserted-by":"publisher","first-page":"E235","DOI":"10.1002\/ajh.25864","volume":"95","author":"XX Cao","year":"2020","unstructured":"Cao XX, Li J, Zhao AL, He TH, Gao XM, Cai HC, et al. Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: a single arm, single center, prospective phase 2 study. Am J Hematol. 2020;95:E235\u20138.","journal-title":"Am J Hematol"},{"key":"2174_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2174_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ajh.26412","volume":"97","author":"XX Cao","year":"2022","unstructured":"Cao XX, Duan MH, Zhao AL, Cai H, Chen J, Gao XM, et al. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis. Am J Hematol. 2022;97:203\u20138.","journal-title":"Am J Hematol"},{"key":"2174_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-72","volume":"8","author":"M Girschikofsky","year":"2013","unstructured":"Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.","journal-title":"Orphanet J Rare Dis"},{"key":"2174_CR16","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.1182\/bloodadvances.2023010706","volume":"7","author":"G Goyal","year":"2023","unstructured":"Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R, et al. Long-term outcomes among adults with Langerhans cell histiocytosis. Blood Adv. 2023;7:6568\u201378.","journal-title":"Blood Adv"},{"key":"2174_CR17","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","volume":"121","author":"H Gadner","year":"2013","unstructured":"Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006\u201314.","journal-title":"Blood"},{"key":"2174_CR18","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/S0959-8049(03)00672-5","volume":"39","author":"M Arico","year":"2003","unstructured":"Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39:2341\u20138.","journal-title":"Eur J Cancer"},{"key":"2174_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00913-8","volume":"13","author":"HX Han","year":"2023","unstructured":"Han HX, Chang L, Lang M, Lin H, Li J, Duan MH, et al. Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement. Blood Cancer J. 2023;13:135.","journal-title":"Blood Cancer J"},{"key":"2174_CR20","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","volume":"34","author":"S Heritier","year":"2016","unstructured":"Heritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34:3023\u201330.","journal-title":"J Clin Oncol"},{"key":"2174_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","volume":"567","author":"EL Diamond","year":"2019","unstructured":"Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521\u20134.","journal-title":"Nature"},{"key":"2174_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: Analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. Jama Oncol. 2018;4:384\u20138.","journal-title":"Jama Oncol"},{"key":"2174_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.18964","volume":"203","author":"AS Reiner","year":"2023","unstructured":"Reiner AS, Durham BH, Yabe M, Petrova-Drus K, Francis JH, Rampal RK, et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol. 2023;203:389\u201394.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02174-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:03:50Z","timestamp":1712329430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02174-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02174-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all patients included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Consent for publication was obtained from all patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}